# US 6,727,287 B2 · Toluene sulfonamide-containing anti-tumor composition and method of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,287 B2
- Document ID: US6727287B2
- Status: Granted
- Kind: B2
- Application number: 09/835,908
- Filed: 2001-04-16
- Published: 2003-01-30
- Granted: 2004-04-27
- Earliest claimed: 2001-04-16
- Assignees: PTS International, Inc.
- Inventors: John Y. J. Wu; Rocky C. S. Shih; Lester J. Wu
- Web page: https://patentgrep.com/patent/US6727287B2

## CPC

- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to compositions which exhibit anti-tumor activity and which comprise a toluene sulfonamide at a concentration not previously recognized as being efficacious for this purpose. The compositions exhibit the ability to inhibit tumor growth, shrink (i.e., necrotize) tumors, and prevent tumor formation in humans. The invention also includes methods of making and using the compositions.

## Claims

### Claim 1

A pharmaceutical composition exhibiting anti-tumor activity, the composition comprising less than 10%, by weight, of a toluene sulfonamide and a pharmaceutically acceptable aqueous carrier selected from the group consisting of an injectable carrier, an infusible carrier and a palatable, orally-administrable carrier.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the toluene sulfonamide is selected from the group consisting of para-toluene sulfonamide, ortho-toluene sulfonamide, meta-toluene sulfonamide, N-ethyl ortho-toluene sulfonamide, N-ethyl para-toluene sulfonamide, and N-cyclohexyl para-toluene sulfonamide.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, comprising at least two toluene sulfonamides.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein each toluene sulfonamide is independently selected from the group consisting of para-toluene sulfonamide, ortho-toluene sulfonamide, meta-toluene sulfonamide, N-ethyl ortho-toluene sulfonamide, N-ethyl para-toluene sulfonamide, and N-cyclohexyl para-toluene sulfonamide.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, further comprising an additional ingredient selected from the group consisting of polyethylene glycol, 2-ethyl-1,3-hexanediol, propanediol, decanedioic acid, dimethyl sulfoxide, ethanol, honey, a surfactant, and an emulsifier.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises up to 90%, by weight, polyethylene glycol.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises up to 90%, by weight, 2-ethyl-1,3-hexanediol.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises up to 90%, by weight, propanediol.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises up to 50%, by weight, decanedioic acid.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises up to 25%, by weight, dimethyl sulfoxide.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises up to 50%, by weight, ethanol.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises para-toluene sulfonamide.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the composition further comprises polyethylene glycol.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the composition further comprises 2-ethyl-1,3-hexanediol.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, comprising para-toluene sulfonamide, polyethylene glycol, 2-ethyl-1,3-hexanediol, propanediol, dimethyl sulfoxide, and ethanol.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein the composition is palatable and further comprises honey.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1, comprising less than about 7% by weight of the toluene sulfonamide.

### Claim 18 (depends on 1)

The pharmaceutical composition of claim 1, comprising less than about 3% by weight of the toluene sulfonamide.

### Claim 19 (depends on 1)

The pharmaceutical composition of claim 1, comprising less than about 1% by weight of the toluene sulfonamide.

### Claim 20

A method of making a pharmaceutical composition exhibiting anti-tumor activity, the method comprising combining a toluene sulfonamide and a pharmaceutically acceptable aqueous carrier to form the composition, wherein the carrier is selected from the group consisting of an injectable carrier, an infusible carrier and a palatable, orally-administrable carrier, and wherein the composition comprises less than 10% by weight of the toluene sulfonamide.

### Claim 21

A method of inhibiting growth of a tumor in a human patient, the method comprising administering to the patient an aqueous pharmaceutical composition comprising less than 10%, by weight, of a toluene sulfonamide, thereby inhibiting growth of the tumor.

### Claim 22

A method of shrinking a tumor in a human patient, the method comprising administering to the patient an aqueous pharmaceutical composition comprising less than 10%, by weight, of a toluene sulfonamide, thereby shrinking the tumor.

### Claim 23

A method of preventing a tumor in a human patient at risk for developing a tumor, the method comprising administering to the patient an aqueous pharmaceutical composition comprising less than 10%, by weight, of a toluene sulfonamide, thereby preventing development of the tumor.

### Claim 24

A palatable, aqueous anti-tumor pharmaceutical composition formulated for oral administration to a patient, the composition comprising less than 10%, by weight, of a toluene sulfonamide.

### Claim 25 (depends on 1)

The pharmaceutical composition of claim 1, wherein the toluene sulfonamide is ortho-toluene sulfonamide.

### Claim 26 (depends on 24)

The method of claim 24, wherein the composition is palatable and administered orally to the patient.

### Claim 27 (depends on 26)

The method of claim 26, wherein the composition is in a form selected from the group consisting of a liquid and a syrup.

### Claim 28 (depends on 21)

The method of claim 21, wherein the composition is administered by infusion.
